glp 1 agonist dpp 4 inhibitor GLP-1 receptor agonists or DPP-4 inhibitors: How to guide the clinician? Dipeptidyl Peptidase-4 Inhibitors: A Systematic
Description
GLP-1- based treatments for T2DM, such as GLP-1 receptor agonists, dual and triple agonists that activate GLP-1R, GIPR, and glucagon receptors, and dipeptidyl peptidase-4 (DPP-4) inhibitors have been reviewed here
A retrospective cohort study based on administrative claims data of 32,800 exenatide patients who were propensity score matched to patients treated with MET or glyburide found no increased risk for either benign thyroid neoplasms (RR 0.7
In comparison, the STEP 1 trial that included semaglutide with general nutrition and physical activity instructions demonstrated a 14.9 % weight reduction from baseline (versus 2.4 % with general nutrition and physical activity instructions alone) [14]
Many of these medications are generic and produced overseas, primarily in India and China
